Clinical trial · Interventional
Levothyroxine Treatment in Thyroid Benign Nodular Goiter
NCT00552253CI-TRIAL-00004219completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
We will study the effect of taking eltroxin at different time, i.e. fasting or postprandial periods. We will also study the effect of levothyroxin treatment in Chinese people
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Thyroid Nodule | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Levothyroxin treatment | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 1
- description
- under eltroxin
- interventionNames
- Drug: Levothyroxin treatment
Primary outcomes (1)
- measure
- The size of thyroid nodules
- timeFrame
- 3 months after levothyroxine treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: 1. age between 20 to 90 years old 2. Benign nodular goiter diagnosed with thyroid echo and fine-needle - aspiration cytology Exclusion Criteria: 1. Age younger than 20 or older than 90 years old 2. Pregnancy 3. Allergy to eltroxin 4. Taking other drugs which will have drug interaction with eltroxin 5. patients with cardiovascular disease, hypertension, gastrointestinal disease
References
Publications (0)
Data not yet available
No reference posted for this study.